A Phase 1 interventional study of DC-806 and [14C]-DC-806 in Healthy Volunteers, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-04.
Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 μCi) of [14C]-DC-806 in urine and feces.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of unlabeled DC-806 tablets followed by DC-806 capsule containing 3.7 MBq (100 μCi) of \[14C\]-DC-806 on Day 1.
Drug: DC-806 · Drug: [14C]-DC-806
Oral tablets
Oral capsules
Renal Clearance (CLr) of DC-806
Time frame: Day 1 to Day 11
CLr of Total Radioactivity
Time frame: Day 1 to Day 11
Cumulative Amount Excreted in Urine (Aeurine) of DC-806
Time frame: Day 1 to Day 11
Aeurine of Total Radioactivity
Time frame: Day 1 to Day 11
Percentage of the Dose Administered Excreted in Urine (Feurine) of DC-806
Time frame: Day 1 to Day 11
Feurine of Total Radioactivity
Time frame: Day 1 to Day 11
Cumulative Amount Excreted in Feces (Aefeces) of Total Radioactivity
Time frame: Day 1 to Day 11
Cumulative Amount Excreted in Vomitus (Aevomitus) of Total Radioactivity
Time frame: Day 1 to Day 11
Percentage of the Dose Administered Excreted in Feces (Fefeces) of Total Radioactivity
Time frame: Day 1 to Day 11
Percentage of the Dose Administered Excreted in Vomitus (Fevomitus) of Total Radioactivity
Time frame: Day 1 to Day 11
Total Amount Excreted in Urine, Feces, and Vomitus (Aeurine + Aefeces + Aevomitus) of Total Radioactivity
Time frame: Day 1 to Day 11
Total Percentage of the Dose Administered Excreted in Urine, Feces, and Vomitus (Feurine + Fefeces + Fevomitus) of Total Radioactivity
Time frame: Day 1 to Day 11
Maximum Observed Concentration (Cmax) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
Cmax of DC-806 in Plasma
Time frame: Day 1 to Day 11
Cmax of Total Radioactivity in Whole Blood
Time frame: Day 1 to Day 11
Cmax of Total Radioactivity in Plasma
Time frame: Day 1 to Day 11
Time to Cmax (tmax) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
tmax of DC-806 in Plasma
Time frame: Day 1 to Day 11
tmax of Total Radioactivity in Whole Blood
Time frame: Day 1 to Day 11
tmax of Total Radioactivity in Plasma
Time frame: Day 1 to Day 11
Area Under the Concentration-time Curve (AUC) up to Time t, where t is the Last Point with Concentrations Above the Lower Limit of Quantification (AUC0-t) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
AUC0-t of DC-806 in Plasma
Time frame: Day 1 to Day 11
AUC0-t of Total Radioactivity in Whole Blood
Time frame: Day 1 to Day 11
AUC0-t of Total Radioactivity in Plasma
Time frame: Day 1 to Day 11
AUC from time 0 to infinity (AUC0-inf) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
AUC0-inf of DC-806 in Plasma
Time frame: Day 1 to Day 11
AUC0-inf of Total Radioactivity in Whole Blood
Time frame: Day 1 to Day 11
AUC0-inf of Total Radioactivity in Plasma
Time frame: Day 1 to Day 11
Apparent Terminal Elimination Rate Constant (λz) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
λz of DC-806 in Plasma
Time frame: Day 1 to Day 11
λz of Total Radioactivity in Whole Blood
Time frame: Day 1 to Day 11
λz of Total Radioactivity in Plasma
Time frame: Day 1 to Day 11
Apparent Terminal Elimination Half-life (t1/2) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
t1/2 of DC-806 in Plasma
Time frame: Day 1 to Day 11
t1/2 of Total Radioactivity in Whole Blood
Time frame: Day 1 to Day 11
t1/2 of Total Radioactivity in Plasma
Time frame: Day 1 to Day 11
Apparent Total Clearance (CL/F) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
CL/F of DC-806 in Plasma
Time frame: Day 1 to Day 11
Apparent Volume of Clearance (Vz/F) of DC-806 in Whole Blood
Time frame: Day 1 to Day 11
Vz/F of DC-806 in Plasma
Time frame: Day 1 to Day 11
Cmax of Total Radioactivity Blood to Plasma Ratio
Time frame: Day 1 to Day 11
AUC0-inf of Total Radioactivity Blood to Plasma Ratio
Time frame: Day 1 to Day 11
Number of Participants who Experience an Adverse Event
Time frame: Up to a maximum of 25 days
Plasma, Whole Blood, Urine, and Feces Concentrations of DC-806 Major Metabolites
Time frame: Day 1 to Day 11
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Oct 2023, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DC-806
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company →